On June 1, 2016, EMA announced the outcome of the assessment of the first batch of applications received from medicine developers for its PRIME (PRIority MEdicines) scheme, a new initiative that aims to foster research on and development of medicines that have the potential to address an unmet medical need. Eighteen applications for PRIME were received as of April 6, 2016, and subsequently assessed by EMA's Scientific Advice Working Party, Committee for Advanced Therapies, and Committee for Medicinal Products for Human Use. Four medicines have been accepted for PRIME.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.